Optimal management of adult cystic fibrosis patients in an outpatient department

1. Капранов И.И., Рачинский С.В. Муковисцидоз. М.; 1995.

2. Капранов Р.И. Современные проблемы и достижения в области изучения муковисцидоза в России. Пульмонология 1994; 3: 6—16.

3. Капранов Н.И., Каширская Н.Ю., Симонова О.И., Шабалова Л.А. Актуальные проблемы муковисцидоза в России на современном этапе. Республиканская программа по совершенствованию диагностики, лечения и медико-социальной помощи больным муковисцидозом (на 1998—2000 г.г.). М.; 1998.

4. Чучалин А .Г., Воронина Л.М., Кронина Л.А., Самсонова М.В. Муковисцидоз у взрослых: этиология, патогенез, перспективы лечения. Пульмонология 1994; 3: 17—23.

5. Шабалова Л.А. Антимикробная терапия при муковисцидозе у детей. 27—32.

6. Aitken М.L., Burke W., McDonald G. et al. Recombinant human DN-ase inhalation in normal subject and pa tien ts with cystic fibrosis: a phase I study. J.A.M.A. 1992; 267: 1947—1951.

7. Bisgaard H., Nielsen K., Skov M. et al. Inhaled steroid treatment of CF patients with chronic Pseudomonas aeruginosa lung infection. Ibid.1994; suppl.10: 289.

8. Bosso J.A. Use of ciprofloxacin in cystic fibrosis patients. Am. J. Med. 1989; suppl: SI23—SI27.

9. Davis P., Drumm M., Konstan M.W. Cystic fibrosis. Am. J. Respir. Crit. Care Med. 1996; 154: 1229—1256.

10. de Groot R., Smith A.L. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significances. Clin. Pharmacokinet. 1987; 13: 228—253.

11. Eigen H., Rosenstein В. J., Fitzsimmons S. et al. A multicenter study of alternate-day prednisolone therapy in pa tien ts with cystic fibrosis. CF Foundation Prednisolone Trial Group. J. Pediatr. 1995; 126: 515—529.

12. Greally P., Hussain M.J., Vergani D. et al. Interleukin-1-alpha, soluble interleukin-2 receptor, and IgG concentration in cystic fibrosis treated with prednisolone. Arch. Dis. Child. 1994; 71: 35—39.

13. Hodson M.E., Geddes D.M. Cystic fibrosis. London; 1995. 9 9—119, 151—174, 237—257.

14. Iioiby N. Isolation and tre a tm en t cystic fibrosis patients, caused by Pseudomonas (Burkholderia) cepaciau and multiresistant Pseudomonas aeruginosa. Neth. J. Med. 1995; 139 (46): 280—287.

15. Hubbard R.C., McElvaney N.G., Birrer P. et al. A preliminary study of aerosolized recombinant human deoxyribonuclease 1 in the tre a tm en t of cystic fibrosis. N. Engl. J . Med. 1992; 326: 812—815.

16. Konstan M.W., Stern R.C., Doershuk C.F. Efficacy of the Flutter device for airway mucus clearance in p a tien ts with cystic fibrosis. J. Pediatr. 1994; 124: 689—693.

17. Le Bel M., Bergeron M.B., Vallee F. et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob. Agents Chemother. 1986; 30: 260—266.

18. Nikolaizik W.H., Schoni M.H. Pilot study of inhaled corticosteroids on lung function in pa tien ts with cystic fibrosis. J. Pediatr. 1996; 128: 271—274.

19. Pattishall E.N. Longitudinal response of pulmonary function to bronchodilators in cystic fibrosis. Pediatr. Pulmonol. 1990; 9: 80—85.

20. Ramsey B.W., Asley S.J., Aitken M.L et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am. Rev. Respir. Dis. 1993; 148: 145—151.

21. Ramsey B.W., Dorkin H.L., Eisenberg J.D. et al. Efficacy of aerosolized tobramycin in p a tients with cystic fibrosis. N. Engl. J. Med. 1993; 328: 1740—1746.

22. Reed M.D., Stern R.C., Myers C.M. et al. Lack of unique ciprofloxacin pharmacokinetic ch aracteris tics in pa tien ts with cystic fibrosis. J. Clin. Pharmacol. 1988; 28: 691—699.

23. Steen H.G., Redmond A.O., O’Neill D. et al. Evaluation of the PEP mask in cystic fibrosis. Acta Paediatr. Scand. 1991; 80: 51—56.

24. Tonnesen P., Stovring S. Positive expiratory pressure PEP as lung physiotherapy in cystic fibrosis: a pilot study. Eur. J. Respir. Dis. 1984; 65: 419—422.

25. Valerius N.H., Koch C., Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early trea tm en t. Lancet 1991; 338: 725—726.

26. Warwick W.J., Hansen L.G. The long-term effect of the high-frequency chest compression therapy on pulmonary complications of the cystic fibrosis. Pediatr. Pulmonol. 1991; 11: 265—271.